Among the 115 women who had synchronous or metachronous metastases of CRC (76 patients were at stage IV at diagnosis and 39 patients experienced recurrences after curative surgery), the median survival times after initial treatment to progression to stage IV or recurrence were 21 months [95% confidence interval (CI), 1–22 months] in patients with the BRAF mutation and 36 months (95% CI, 26–42 months) in those without the BRAF mutation (BRAF wild type) (P = 0.0014, Figure 2D). The gene discussed is BRAF; the disease is colorectal carcinoma.